Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate

September 30, 2014 Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced favorable safety results from the single ascending dose portion of a Phase I study of AVI-7100, the company‚Äôs lead candidate for the treatment of influenza virus, in healthy volunteers. The clinical trial is being conducted at the National Institutes of Health (NIH) through a collaboration between …